Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
July 27, 2020
HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101
Presentation at Alzheimer’s Association International Conference (AAIC)
